Insmed INSM Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $582.19M+14.1% | $510.45M+52.5% | $334.76M-73.9% | $1.28B+218% | $403.25M-27.3% | ||
| $641.33M-30.3% | $919.6M-31.6% | $1.35B+135% | $572.44M-28.1% | $796.2M-9.4% | ||
| $178.56M+26.8% | $140.86M+116% | $65.26M+18.6% | $55.03M+15.3% | $47.75M-8.2% | ||
| $132.91M+0.6% | $132.07M+9.2% | $120.97M+12.4% | $107.61M+6.8% | $100.71M+2.2% | ||
| $78.2M-14.3% | $91.24M+39.1% | $65.6M+5.5% | $62.18M+13.5% | $54.78M+47.1% | ||
| $1.61B-10.1% | $1.79B-7.1% | $1.93B-7.2% | $2.08B+48.4% | $1.4B-13.5% | ||
| $102.85M-0.1% | $102.94M+14.8% | $89.67M-0.4% | $90M+1.9% | $88.36M+10.4% | ||
| $14M-32.4% | $20.71M+93.4% | $10.71M+3.8% | $10.32M-4.8% | $10.83M-37.2% | ||
| $136.11M0.0% | $136.11M0.0% | $136.11M0.0% | $136.11M0.0% | $136.11M0.0% | ||
| $95.57M-2.1% | $97.65M+15.4% | $84.59M+50.7% | $56.13M-2.2% | $57.39M-2.2% | ||
| $99.28M+2.0% | $97.38M+6.3% | $91.61M+3.2% | $88.81M-1.1% | $89.76M-3.7% | ||
| $2.08B-8.3% | $2.26B-4.1% | $2.36B-4.8% | $2.48B+37.6% | $1.8B-11.0% | ||
| $3.45M+3.0% | $3.35M+3.0% | $3.25M+3.1% | $3.15M+3.1% | $3.05M+3.1% | ||
| $5.01M-47.1% | $9.47M+129% | $4.13M+17.6% | $3.51M+0.2% | $3.51M-62.5% | ||
| $3.45M+3.0% | $3.35M+3.0% | $3.25M+3.1% | $3.15M+3.1% | $3.05M+3.1% | ||
| $361.01M-23.0% | $468.87M+12.4% | $417.21M+33.9% | $311.68M+30.3% | $239.23M-19.6% | ||
| $542.22M+0.2% | $540.96M+0.2% | $539.72M+0.2% | $538.51M-51.3% | $1.11B+0.2% | ||
| $9.84M-19.2% | $12.17M+60.4% | $7.59M-3.9% | $7.9M-6.9% | $8.48M-6.9% | ||
| —— | —— | —— | —— | —— | ||
| $19.82M-4.3% | $20.72M-4.1% | $21.6M-3.8% | $22.44M-3.6% | $23.27M-3.3% | ||
| $5.68M+0.7% | $5.65M+0.9% | $5.6M+0.6% | $5.56M+8.6% | $5.12M+926% | ||
| $1.37B-10.1% | $1.53B+7.8% | $1.42B+15.0% | $1.23B-27.8% | $1.7B-2.1% | ||
| $2.17M+1.0% | $2.14M+0.8% | $2.13M+0.7% | $2.11M+16.1% | $1.82M+1.4% | ||
| $6.5B+2.1% | $6.37B+2.0% | $6.25B+1.1% | $6.18B+31.2% | $4.71B+1.5% | ||
| -$5.8B-2.9% | -$5.64B-6.2% | -$5.31B-7.5% | -$4.94B-7.0% | -$4.62B-5.9% | ||
| $4K-99.7% | $1.46M-26.9% | $2M+15.4% | $1.73M+292% | -$902K+60.6% | ||
| $704.85M-4.6% | $738.98M-21.8% | $945.57M-24.3% | $1.25B+1,160% | $99.16M-65.3% | ||
| $2.08B-8.3% | $2.26B-4.1% | $2.36B-4.8% | $2.48B+37.6% | $1.8B-11.0% | ||
| $641.33M-30.3% | $919.6M-31.6% | $1.35B+135% | $572.44M-28.1% | $796.2M-9.4% | ||
| $14M-32.4% | $20.71M+93.4% | $10.71M+3.8% | $10.32M-4.8% | $10.83M-37.2% | ||
| $95.57M-2.1% | $97.65M+15.4% | $84.59M+50.7% | $56.13M-2.2% | $57.39M-2.2% | ||
| $14M-32.4% | $20.71M+93.4% | $10.71M+3.8% | $10.32M-4.8% | $10.83M-37.2% | ||
| $99.28M+2.0% | $97.38M+6.3% | $91.61M+3.2% | $88.81M-1.1% | $89.76M-3.7% | ||
| $14M-32.4% | $20.71M+93.4% | $10.71M+3.8% | $10.32M-4.8% | $10.83M-37.2% | ||
| $162.14M-0.4% | $162.87M-0.6% | $163.85M+0.2% | $163.53M+0.6% | $162.51M+0.9% | ||
| $352.56M-22.7% | $456.06M+11.3% | $409.84M— | —— | —— | ||
| $270.31M-14.0% | $314.34M+21.1% | $259.6M+43.8% | $180.5M+12.9% | $159.9M+10.9% | ||
| $2.17M+1.0% | $2.14M+0.8% | $2.13M+0.7% | $2.11M+16.1% | $1.82M+1.4% | ||
| $162.14M-0.4% | $162.87M-0.6% | $163.85M+0.2% | $163.53M+0.6% | $162.51M+0.9% | ||
| $3.45M+3.0% | $3.35M+3.0% | $3.25M+3.1% | $3.15M+3.1% | $3.05M+3.1% | ||
| $14.88M-4.4% | $15.56M-4.2% | $16.24M-4.0% | $16.92M-3.9% | $17.6M-3.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Insmed's total assets?
- Insmed (INSM) holds $2.1B in total assets, up 15.2% year over year.
- How much debt does Insmed have?
- Insmed carries $580.3M in total debt against $704.9M of shareholders' equity, a debt-to-equity ratio of 0.82.
- How much cash does Insmed have?
- Insmed holds $582.2M in cash and equivalents.
- Can Insmed cover its short-term obligations?
- Its current ratio is 4.47 — current assets exceed current liabilities.
- Where does Insmed's balance sheet data come from?
- Every line is extracted from Insmed's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
